Pfizer: Hepatitis C trials
The registry lists 14 Hepatitis C studies with Pfizer as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 8Phase 2 5Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver EnzymesTerminatedNCT01226797Phase 2Results posted
- Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 SubjectsCompletedNCT00987337Phase 2Results posted
- A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 InfectionCompletedNCT00720434Phase 2Results posted
- Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.CompletedNCT00671671Phase 1Results posted
- A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive PatientsCompletedNCT00445315Phase 1Results posted
- Investigation Of The Effect Of Steady State Filibuvir On The Pharmacokinetics Of Oral Contraceptives (Levonorgestrel And Ethinyl Estradiol)CompletedNCT00918476Phase 1
- Bioavailability Study Of PF-00868554 Administered As 3x250mg Oral Tablets (Wet Granulate, 3x250mg Oral Tablets (Dry Granulate) And 750mg Solution Under Fed StateCompletedNCT00861458Phase 1
- Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691CompletedNCT00810758Phase 1
- Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554CompletedNCT00651027Phase 1
- A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder SubjectsCompletedNCT00367887Phase 2
- Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy AdultsCompletedNCT00314054Phase 1
- CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Non-Responder (Null And Partial Responder) Hepatitis C Virus (HCV) Genotype 1 Infected SubjectsCompletedNCT00277238Phase 2
- CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) SubjectsCompletedNCT00142103Phase 1
- An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis CCompletedNCT00141284Phase 4